LncRNA PTCSC3 Is a Biomarker for the Treatment and Prognosis of Gastric Cancer

Background: Long noncoding RNA (lncRNA) papillary thyroid carcinoma susceptibility candidate 3 (PTCSC3) inhibits several types of cancer, whereas its role in gastric cancer is unknown. Materials and Methods: From May 2010 to May 2015, this study included 68 (36 males and 32 females, 35-69 years, 48.3 ± 7.1 years) gastric cancer patients and 60 healthy volunteers (32 males and 28 females, 34-67 years, 48.8 ± 6.5 years). Transient transfections, QPCR, CCK-8, transwell cell migration, and invasion assay were used for carrying out the research. Results: The authors found that plasma PTCSC3 was downregulated in gastric cancer patients. Downregulation of PTCSC3 distinguished early stage gastric cancer patients from healthy controls. LncRNA PTCSC3 expression levels were increased on the day of discharge in gastric cancer patients compared with pretreatment levels. During follow-up, patients with low plasma levels of PTCSC3 showed a significantly lower overall survival rate. PTCSC3 negatively regulated proliferation, invasion, and migration of gastric cancer cells. Conclusions: Therefore, lncRNA PTCSC3 may serve as a biomarker for the treatment and prognosis of gastric cancer.